- Cardiovascular disease remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths annually.
- The HeartBeam System enables a patient to capture a 30-second ECG recording with its credit-card-sized, cable-free device, regardless of where they are.
- The HeartBeam-HeartNexus collaboration makes board-certified cardiologists available 24/7 to interpret the results for arrhythmia assessment and provide expert feedback directly to the patient or to a coordinating clinician.
HeartBeam (NASDAQ: BEAT), a medical-technology company developing next-generation cardiac diagnostics via its patented 12-Lead ECG synthesis software, has announced a strategic collaboration with HeartNexus (https://ibn.fm/yyz1i). The partnership will expand access to cardiologist-level ECG insights for arrhythmia assessment anytime, anywhere.
Cardiovascular disease remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths annually according to the World Health Organization (https://ibn.fm/oQxTL). ECGs are the most common cardiac test yet standard ECG testing often requires in-clinic visits, specialized equipment and trained personnel (https://ibn.fm/aQV4K). By enabling cardiologist-level ECG interpretation in a mobile format, HeartBeam’s synthesis ECG platform addresses critical gaps in timely detection and monitoring of arrhythmias, potentially reducing time-to-diagnosis and improving outcomes.
The need for seamless ECG insights is especially relevant in the current healthcare landscape, where telehealth and remote monitoring have accelerated, particularly since the COVID-19 pandemic. Patients managing chronic cardiac conditions, recent hospital discharges or symptoms at home often rely on intermittent teleconsultation.
However, the majority of at-home options rarely offer full 12-lead ECG data or advanced interpretation. With HeartBeam, a patient who is feeling arrhythmia symptoms, such as palpitations, can capture a 30-second recording with the credit-card-sized, cable-free device, regardless of where they are. The device’s patented 3D technology records the heart’s electrical signals in three dimensions and synthesizes the signals into a 12-lead ECG, which is securely transmitted to the HeartNexus team of board-certified cardiologists for immediate review. At that point, a cardiologist interprets the results for arrhythmia assessment and provides expert feedback directly to the patient or to a coordinating clinician. All this is done through HeartBeam’s secure ecosystem, which is slated to include future enhancements such as AI wellness and community features and wearable integration.
Beyond diagnosis, the partnership also has implications for patient engagement and monitoring. Patients at elevated risk for cardiac issues often face frequent clinic visits and standard device check-ups. However, by enabling remote ECG acquisition and analysis, the HeartBeam solution may reduce the burden on patients and health systems while improving adherence and monitoring frequency. Increased data capture and remote surveillance potentially enable proactive intervention, identifying trends or arrhythmias before they escalate and supporting value-based care models focused on prevention and early action.
For investors and industry observers, this collaboration represents a meaningful step in HeartBeam’s commercial strategy. The company’s movement from device development into integrated cardiac care ecosystems indicates scalability and applicability across markets, including telemedicine, home-care monitoring and ambulatory cardiology. As the cardiac care paradigm shifts toward decentralized and continuous monitoring, HeartBeam’s groundbreaking ECG technology paired with on-demand, expert cardiology interpretation from HeartNexus positions it to capture a growing share of the remote cardiac monitoring ecosystem.
For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
